Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 1.00 |
| ▸ | BACE1 | P56817 | 5/20 | 1.00 |
| ▸ | MMP2 | P08253 | 5/20 | 1.00 |
| ▸ | MMP7 | P09237 | 5/20 | 1.00 |
| ▸ | MMP14 | P50281 | 5/20 | 1.00 |
| ▸ | BCL2 | P10415 | 4/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | PGD | P52209 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | PGAM1 | P18669 | 2/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epigalocatechin Gallate SCHEMBL29389587 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Gallocatechin Gallate SCHEMBL30977114 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL30014282 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL30909383 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL10198783 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL14423426 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL35258 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Gallocatechin Gallate SCHEMBL49461 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL13624466 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL8426376 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | claimed |
| US-20250017958-A1 | COMBINATORIAL THERAPEUTIC APPROACH FOR FRIEDREICH'S ATAXIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-01-16 | — | — | US | disclosed |
| US-12138261-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-11-12 | — | — | US | disclosed |
| EP-4380633-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023191839-A9 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023191839-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11701402-B2 | Polypharmaceutical drug compositions and related methods | AVETA BIOMICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701402-B2 | Polypharmaceutical drug compositions and related methods | AVETA BIOMICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20110071071-A1 | PSMB10: A DIAGNOSIS MARKER AND THERAPEUTIC TARGET OF CHRONIC REJECTION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-03-24 | — | — | US | disclosed |
| US-20100021989-A1 | COMPOSITIONS AND METHODS OF CONTROLLING AND ADMINISTERING REDOX SPECIFIC FORMS OF DRUGS, FOODS AND DIETARY SUPPLEMENTS | CURAPHARM, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20090294298-A1 | Detection of Phenols | ISIS INNOVATION LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090294298-A1 | Detection of Phenols | ISIS INNOVATION LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090181079-A1 | METHODS OF MAKING AND USING THEAFLAVIN, THEAFLAVIN-3-GALLATE, THEAFLAVIN-3'-GALLATE AND THEAFLAVIN 3,3'-DIGALLATE AND MIXTURES THEREOF | NASHAI BIOTECH, LLC | 2009-07-16 | — | — | US | disclosed |
| EP-1460999-B1 | METHODS OF MAKING AND USING THEAFLAVIN, THEAFLAVIN-3-GALLATE, THEAFLAVIN-3'-GALLATE AND THEAFLAVIN 3,3'-DIGALLATE AND MIXTURES THEREOF | NASHAI BIOTECH LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-20080306143-A1 | Cathechins for the Treatment of Fibrillogenesis in Alzheimer's Disease, Parkinson's Disease, Systemic AA Amyloidosis, and Other Amyloid Disorders | PROTAMED, INC. | 2008-12-11 | — | — | US | disclosed |
| US-7427622-B2 | Method of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof | NASHAI BIOTECH, LLC (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1852430-A1 | METHOD OF PRODUCING PROANTHOCYANIDIN OLIGOMER | Nagasaki University (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | DYRK1A 727/4885BACE1 2912/4885MMP2 1932/4885 |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | BCLAF1, BID, BCL2L1 | DYRK1A 2545/4885BACE1 2773/4885MMP2 3641/4885 |
| US-20250017958-A1 | COMBINATORIAL THERAPEUTIC APPROACH FOR FRIEDREICH'S ATAXIA | ATXN2, HTT, ATXN10 | DYRK1A 2384/4885BACE1 2199/4885MMP2 4589/4885 |
| US-20110071071-A1 | PSMB10: A DIAGNOSIS MARKER AND THERAPEUTIC TARGET OF CHRONIC REJECTION | PSMB10, PSMB5, PSMB1 | DYRK1A 4458/4885BACE1 2715/4885MMP2 3385/4885 |
| US-11701402-B2 | Polypharmaceutical drug compositions and related methods | PCBP1, CYP3A5, ABCB1 | DYRK1A 2796/4885BACE1 1152/4885MMP2 4763/4885 |
| US-12138261-B2 | Inhibitors of Bcl-2 | BCL2, BAX, BAK1 | DYRK1A 1862/4885BACE1 2507/4885MMP2 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.